Literature DB >> 20594133

Stem cell treatment for Crohn's disease.

Julián Panés1, Ingrid Ordás, Elena Ricart.   

Abstract

While stem cell-based treatments have been established as a clinical standard of care for some conditions, such as hematopoietic stem cell transplants for cancer, the scope of potential stem cell-based therapies has expanded in recent years due to advances in stem cell research, paving the way for the increasing utilization of stem cell therapies in severe immune-mediated diseases including inflammatory bowel diseases (IBDs) and, in particular, Crohn's disease. Both hematopoietic stem cells and mesenchymal (stromal) stem cells are considered to be of potential therapeutic benefit in immune-mediated conditions. A growing body of experimental and clinical evidence shows that hematopoietic stem cell transplant induces long-lasting remission in a majority of patients with active severe Crohn's disease refractory to drug treatments, and the differential effect of potent immunosuppression and immune reconstitution in this setting is under evaluation. Mesenchymal stem cells have been shown to exert immunomodulatory action on various types of immune-mediated diseases, and in experimental models of IBD, but evaluation of the potential efficacy of this therapy in IBD is still in the early stages.

Entities:  

Mesh:

Year:  2010        PMID: 20594133     DOI: 10.1586/eci.10.27

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  5 in total

Review 1.  Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy.

Authors:  Julián Panés; Jordi Rimola
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-09       Impact factor: 46.802

2.  Mesenchymal stem cells as a novel vaccine platform.

Authors:  Suzanne L Tomchuck; Elizabeth B Norton; Robert F Garry; Bruce A Bunnell; Cindy A Morris; Lucy C Freytag; John D Clements
Journal:  Front Cell Infect Microbiol       Date:  2012-11-16       Impact factor: 5.293

Review 3.  From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases.

Authors:  Raghavan Chinnadurai; Edmund K Waller; Jacques Galipeau; Ajay K Nooka
Journal:  Biomed Res Int       Date:  2013-11-19       Impact factor: 3.411

Review 4.  The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses.

Authors:  Elizabeth S MacDonald; Jennifer G Barrett
Journal:  Front Vet Sci       Date:  2020-01-21

5.  Toll-like receptor 3 and suppressor of cytokine signaling proteins regulate CXCR4 and CXCR7 expression in bone marrow-derived human multipotent stromal cells.

Authors:  Suzanne L Tomchuck; Sarah L Henkle; Seth B Coffelt; Aline M Betancourt
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.